Results 51 to 60 of about 31,287 (242)

Persistent Bilateral [18F]THK5351 and Migrating Unilateral [18F]FDG Uptake in Anti‐LGI1 Encephalitis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Anti–leucine‐rich glioma‐inactivated 1 encephalitis (LGI1‐E) can cause persistent cognitive deficits, but the mechanisms remain unclear. A 40‐year‐old woman with LGI1‐E presented with subacute cognitive deficits and showed mild left medial temporal lobe (MTL) swelling and fluid‐attenuated inversion recovery (FLAIR) hyperintensity on initial ...
Yusuke Akitomi, Kenichiro Taira, Masanori Kurihara, Kenji Ishibashi, Kenji Ishii, Fumio Suzuki, Aya Midori Tokumaru, Makoto Hara, Atsushi Iwata   +8 more
wiley   +1 more source

Combination therapy for management of pemphigus patients with unexpected therapeutic response to rituximab: A report of five cases

Clinical Case Reports, 2023
Key Clinical Message The immunosuppressant agents should be considered earlier in the course of treatment with rituximab, possibly after the unfavorable response at first cycle of treatment, especially in male patients and those with high BMI.
Zeinab Aryanian, Insha Zainab Riyaz, Kamran Balighi, Ali Ahmadzade, Hamid Reza Mahmoudi, Arghavan Azizpour, Parvaneh Hatami   +6 more
doaj   +1 more source

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin, Binbin Xue, Dewei Xie, Jia Li, Juyuan Pan, Lanbing Zhu, Qiaowen Tong, Jing Lin, Ruofan Zhu, Xu Zhang, Junhui Xia, Xiang Li   +11 more
wiley   +1 more source

Real-World Evidence Assessing the Safety of Administering Intravenous Rituximab Biosimilar in the First Cycle and Subcutaneous Rituximab in Subsequent Cycles in B-Cell Lymphoma Patients

Pharmacy
Background: Biosimilar versions of rituximab have similar safety and efficacy as the reference product across all indications based on the extrapolation principle. Our organization replaced intravenous (IV) rituximab (Mabthera) with IV rituximab (Truxima-
Tamather Almandeel, Mansoor Ahmed Khan, Ashwag Algethami, Mashael S. Alaboud, Munirah A. Alkathiri, Mohammed Aseeri, Ahmed Absi, Mubarak Almansour, Abdullah Alotaibi   +8 more
doaj   +1 more source

Rituximab in Minimal Change Disease

Canadian Journal of Kidney Health and Disease, 2017
Treatment with rituximab, a monoclonal antibody against the B-lymphocyte surface protein CD20, leads to the depletion of B cells. Recently, rituximab was reported to effectively prevent relapses of glucocorticoid-dependent or frequently relapsing minimal
Nima Madanchi, Martin Bitzan, Tomoko Takano   +2 more
doaj   +1 more source

Tumor uptake on ⁸⁹Zr-rituximab-PET, discordant with CD20 expression in biopsy.

, 2017
Axial images, from left to right attenuation corrected PET, low dose CT and fused PET/CT image of patient 6. a) 89Zr-rituximab-PET shows tumor uptake discordant with a CD20-negative biopsy (axillar lymph node).
Guus A. M. S. van Dongen (506975), Daphne de Jong (3622187), Danielle J. Vugts (506973), Otto S. Hoekstra (300973), Yvonne W. S. Jauw (3622184), Josée M. Zijlstra (3622181), Sonja Zweegman (482354), Marc C. Huisman (3622178)   +7 more
core   +1 more source

Anti‐CD19 CAR T Cells in Autoimmune Encephalitis: Inflammation Controlled, Neurodegeneration Unchecked?

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Just recently, successful chimeric antigen receptor (CAR) T cell therapy was reported in the first patient with refractory, anti‐diacylglycerol lipase alpha (DAGLA) antibody‐mediated autoimmune encephalitis, achieving partial clinical remission.
Dimitrios Mougiakakos, Marwa Al‐Dubai, Denise Walther, Dominic Borie, Jan D. Lünemann, Marc Pawlitzki, Sven G. Meuth, Solveig Henneicke, Stefan Vielhaber, Stefanie Schreiber   +9 more
wiley   +1 more source

Effectiveness and patient-reported impact of on-flare retreatment in patients with rheumatoid arthritis: insights from retrospective long-term real-world data

BMC Rheumatology
Background Rituximab is known as an efficacious drug for the treatment of Rheumatoid Arthritis (RA). The original administration schedule consisted of two infusions of 1000 mg with a 2-week interval.
Delphine Bertrand, Elias De Meyst, Michaël Doumen, Diederik De Cock, Johan Joly, Barbara Neerinckx, Sofia Pazmino, Nele Pype, Tom Conings, René Westhovens, Patrick Verschueren   +10 more
doaj   +1 more source

Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies

Kidney International Reports
Introduction: Although rituximab has significantly improved outcomes for patients with membranous nephropathy, response to treatment is not universal and drug resistance can occur.
Maxime Teisseyre, Marco Allinovi, Vincent Audard, Marion Cremoni, Giulia Belvederi, Alexandre Karamé, Matteo Accinno, Julien Duquesne, Vinod Sharma, Céline Fernandez, Kévin Zorzi, Mounir El Maï, Vesna Brglez, Sylvia Benzaken, Vincent L.M. Esnault, Alessandra Vultaggio, Harbir Singh Kohli, Raja Ramachandran, Calogero Lino Cirami, Barbara Seitz-Polski   +19 more
doaj   +1 more source

METTL3-mediated m6A methylation of C1qA regulates the Rituximab resistance of diffuse large B-cell lymphoma cells

Cell Death Discovery, 2023
Rituximab has been incorporated into the standard treatment regimen for diffuse large B-cell lymphoma (DLBCL), and induces the death of tumor cells via complement-dependent cytotoxicity (CDC).
Junping Li, Zhigang Zhu, Yuan Zhu, Jinqing Li, Kangbao Li, Weijie Zhong   +5 more
doaj   +1 more source